Dermata Therapeutics

Q2 FY2026 EarningsQ2 FY26 results missed consensus across all bottom-line metrics as the company transitions to a commercial skincare stage. Revenue of $0 was in-line with expectations, while Net Loss of $2.97M was 34% wider than the expected $2.21M. EPS of -$0.74 missed the -$0.55 consensus by $0.19, driven by a sharp 142% YoY increase in SG&A expenses related to the upcoming launch of Tome™ Foundational Treatment on August 25, 2026. Cash runway is guided into Q4 2026.